Cancer metabolism provides innovative opportunities for next-generation anticancer therapies that could be further improved using novel NR4A1 agonists or antagonists that simultaneously regulate NR4A1 and its downstream signaling pathways. This evidence concerns the gene NR4A1 and cancer.